Search
Sevoflurane
go.drugbank.com/drugs/DB01236ApprovedInvestigationalVet approvedSevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 SubstratesGliquidone
go.drugbank.com/drugs/DB01251ApprovedGliquidone is a sulfonylurea drug used to treat diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, an...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesLumiracoxib
go.drugbank.com/drugs/DB01283ApprovedWithdrawnLumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Aust...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesOxtriphylline
go.drugbank.com/drugs/DB01303ApprovedOxtriphylline is the choline salt form of theophylline. Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Its main physiological reponse i...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesAmobarbital
go.drugbank.com/drugs/DB01351ApprovedIllicitA barbiturate with hypnotic and sedative properties (but not antianxiety). Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmac...
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersHexobarbital
go.drugbank.com/drugs/DB01355ExperimentalA barbiturate that is effective as a hypnotic and sedative.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesCortisone acetate
go.drugbank.com/drugs/DB01380ApprovedInvestigationalCortisone acetate was first isolate in 1935 and became more widely researched in 1949. Since then, glucocorticoids such as cortisone acetate have been used to treat a number of inflammatory conditions such as endocrine, rheumatic, collag...
Categories: P-glycoprotein inducers, P-glycoprotein substratesBezafibrate
go.drugbank.com/drugs/DB01393ApprovedInvestigationalAntilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins.
Synonyms: 2-(p-(2-(p-Chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acidCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsColchicine
go.drugbank.com/drugs/DB01394ApprovedInvestigationalColchicine is an alkaloid drug derived from a plant belonging to the Lily family, known as Colchicum autumnale, or "autumn crocus." Its use was first approved by the FDA in 1961. Colchicine is used in the treatment of gout flares and Fam...
Categories: P-glycoprotein inducers, P-glycoprotein substratesDigitoxin
go.drugbank.com/drugs/DB01396ApprovedWithdrawnA cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665)
Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates